Comparison of survival outcomes for axillary surgery extent based on intraoperative sentinel lymph node biopsy result after neoadjuvant chemotherapy for breast cancer

[1] King TA(2015)Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy Nat Rev Clin Oncol 12 335-343

[2] Morrow M(2016)Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3398 patients Am J Surg 212 969-981

[3] El Hage CH(2017)Axillary nodal management following neoadjuvant chemotherapy: a review JAMA Oncol 3 549-555

[4] Headon H(2020)ASO author reflections: omission of axillary lymph node dissection for breast cancer patients with residual N1 nodal disease following neoadjuvant chemotherapy: not ready for primetime? Ann Surg Oncol 27 869-870

[5] El Tokhy O(2017)Are the ACOSOG Z0011 trial findings being applied to breast cancer patients undergoing neoadjuvant chemotherapy? Breast J 23 554-562

[6] Heeney J(2013)Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial JAMA 310 1455-1461

[7] Kasem A(2013)Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy SENTINA a prospective, multicentre cohort study Lancet Oncol 14 609-618

[8] Mokbel K(2015)Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study J Clin Oncol 33 258-264

[9] Pilewskie M(2017)Use of sentinel Lymph node dissection after neoadjuvant chemotherapy in patients with node-positive breast cancer at diagnosis: practice patterns of american society of breast surgeons members Ann Surg Oncol 24 2925-2934

[10] Morrow M(2017)Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial JAMA 318 918-926

[1] King TA(2015)Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy Nat Rev Clin Oncol 12 335-343

[2] Morrow M(2016)Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3398 patients Am J Surg 212 969-981

[3] El Hage CH(2017)Axillary nodal management following neoadjuvant chemotherapy: a review JAMA Oncol 3 549-555

[4] Headon H(2020)ASO author reflections: omission of axillary lymph node dissection for breast cancer patients with residual N1 nodal disease following neoadjuvant chemotherapy: not ready for primetime? Ann Surg Oncol 27 869-870

[5] El Tokhy O(2017)Are the ACOSOG Z0011 trial findings being applied to breast cancer patients undergoing neoadjuvant chemotherapy? Breast J 23 554-562

[6] Heeney J(2013)Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial JAMA 310 1455-1461

[7] Kasem A(2013)Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy SENTINA a prospective, multicentre cohort study Lancet Oncol 14 609-618

[8] Mokbel K(2015)Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study J Clin Oncol 33 258-264

[9] Pilewskie M(2017)Use of sentinel Lymph node dissection after neoadjuvant chemotherapy in patients with node-positive breast cancer at diagnosis: practice patterns of american society of breast surgeons members Ann Surg Oncol 24 2925-2934

[10] Morrow M(2017)Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial JAMA 318 918-926